We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Hematology Analyzer Evaluated for Cerebrospinal Fluid Testing

By LabMedica International staff writers
Posted on 04 Apr 2012
Print article
One of newest generation hybrid hematology analyzer is equipped with an improved body fluid analysis mode that is suitable for cerebrospinal fluid (CSF) analysis.

The cellular components of CSF have conventionally been enumerated microscopically by using a hemocytometer-counting chamber, but this is labor intensive and time consuming, and maybe replaced by a hematology autoanalyzer.

Laboratory scientists at the Medical University of Vienna (Austria) analyzed a total of 425 consecutive CSF samples sent to the Department of Laboratory Medicine for routine testing. Microscopic cell counts were performed by biomedical technicians using a Fuchs-Rosenthal counting chamber after samples were stained with methyl violet acetic acid.

CSF samples were measured for white blood cells (WBCs) using the body fluid mode of the XE-5000 Hematology Analyzer. By combining fluorescent dye binding and semiconductor laser technology, the XE-5000 (Sysmex Corporation; Kobe, Japan) differentiates between WBCs that are mononuclear cells (MN), including lymphocytes and monocytes and those that are polymorphonuclear cells (PMN), including all types of granulocytes.

For total WBC counts, the proportions of samples correctly classified by the XE-5000 from different groups were: 88% for 0 to 5 WBC/µL in 330 samples; 47% for 6 to10 WBC/µL in 36 samples; 72% for 11 to 50 WBC/µL in 39 samples; 93% for 51 to 200 WBC/µL in15 samples; and 100% for cell counts above 200 WBC/µL. After the two lowest count categories were combined into one range of 0 to10 WBC/µL, matches increased to 95%. For PMN counts in the 0% to 25% group, 37% of samples were misclassified by the XE-5000. Conversely, for samples with microscopic PMN counts of more than 25%, there was a trend toward underestimation by the XE-5000. Mismatches were most pronounced in samples with fewer than 10 WBC/µL.

The authors concluded that based on the results of their study, they felt confident in recommending the XE-5000 as a reliable WBC counter for CSF, even for samples with low WBC counts, which comprise most laboratory admissions. It was previously recommended that all samples with cell counts of less than 5 and more than 20 WBC/µL on the XE-5000 be manually recounted, but the authors propose selecting samples for microscopic rework based on their DIFF channel scattergrams rather than predefined WBC count results. However, it cannot be recommended as a suitable alternative for manual differential cytological workup. The study was published in the February 2012 edition of the journal Archives of Pathology & Laboratory Medicine.

Related Links:

Medical University of Vienna
Sysmex Corporation



Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.